title: Angiogenesis in male breast cancer.
abstract: BACKGROUND: Male breast cancer is a rare but aggressive and devastating disease. This disease presents at a later stage and in a more advanced fashion than its female counterpart. The immunophenotype also appears to be distinct when compared to female breast cancer. Angiogenesis plays a permissive role in the development of a solid tumor and provides an avenue for nutrient exchange and waste removal. Recent scrutiny of angiogenesis in female breast cancer has shown it to be of significant prognostic value. It was hypothesized that this holds true in invasive ductal carcinoma of the male breast. In the context of male breast cancer, we investigated the relationship of survival and other clinico-pathological variables to the microvascular density of the tumor tissue. METHODS: Seventy-five cases of primary male breast cancer were identified using the records of the Saskatchewan Cancer Agency over a period of 26 years. Forty-seven cases of invasive ductal carcinoma of the male breast had formalin-fixed paraffin-embedded tissue blocks that were suitable for this study. All cases were reviewed. Immunohistochemical staining was performed for the angiogenic markers (cluster designations 31 (CD31), 34 (CD34) and 105 (CD105), von Willebrand factor (VWF), and vascular endothelial growth factor (VEGF)). Microvascular density (MVD) was determined using average, centre, and highest microvessel counts (AMC, CMC, and HMC, respectively). Statistical analyses compared differences in the distribution of survival times and times to relapse between levels of MVD, tumor size, node status and age at diagnosis. In addition, MVD values were compared within each marker, between each marker, and were also compared to clinico-pathological data. RESULTS: Advanced age and tumor size were related to shorter survival times. There were no statistically significant differences in distributions of survival times and times to relapse between levels of MVD variables. There was no significant difference in MVD between levels of the different clinico-pathological variables. MVD was strongly and significantly correlated between AMC, CMC and HMC for CD31, CD34, and CD105 (p < 0.01) and remained moderate to weak for VWF and VEGF. CONCLUSION: Microvascular density does not appear to be an independent prognostic factor in male breast cancer. However, the likelihood of death for men with breast cancer is increased in the presence of increased age at diagnosis and advanced tumor size. This is perhaps linked to inherent tumor vasculature, which is strongly related throughout a tumor section.
authors.affiliation: Department of Pathology, University of Saskatchewan, Royal University Hospital, 103 Hospital Drive, Saskatoon, Canada. inarkanth@shaw.ca.
authors.forename: Evan M
authors.initials: EM
authors.lastname: Frangou
authors.forename: Joshua
authors.initials: J
authors.lastname: Lawson
authors.forename: Rani
authors.initials: R
authors.lastname: Kanthan
references.citation: Annu Rev Biochem. 1998;67:395-424
references.pmid: 9759493
references.citation: J Cell Biol. 1995 Jul;130(2):451-60
references.pmid: 7542249
references.citation: Am J Physiol Cell Physiol. 2001 Jun;280(6):C1367-74
references.pmid: 11350731
references.citation: Eur J Cancer. 1995 Nov;31A(12):1960-4
references.pmid: 8562148
references.citation: Oncogene. 2000 Dec 11;19(53):6122-9
references.pmid: 11156525
references.citation: Cancer. 1999 Feb 1;85(3):629-39
references.pmid: 10091736
references.citation: Science. 1993 Dec 3;262(5139):1580-2
references.pmid: 8248808
references.citation: Hum Pathol. 1995 Nov;26(11):1196-200
references.pmid: 7590692
references.citation: Blood. 1986 Mar;67(3):842-5
references.pmid: 3947749
references.citation: J Exp Med. 1992 May 1;175(5):1401-4
references.pmid: 1569405
references.citation: J Exp Med. 1994 Mar 1;179(3):1059-64
references.pmid: 8113674
references.citation: Am Surg. 1994 Nov;60(11):816-20
references.pmid: 7978672
references.citation: J Exp Med. 1990 Jun 1;171(6):2147-52
references.pmid: 2351935
references.citation: J Invest Dermatol. 1995 Jul;105(1):44-50
references.pmid: 7615975
references.citation: Br J Surg. 1997 Apr;84(4):433-5
references.pmid: 9112887
references.citation: Surg Clin North Am. 1996 Apr;76(2):343-63
references.pmid: 8610268
references.citation: J Biol Chem. 1993 Jul 25;268(21):16037-46
references.pmid: 8340425
references.citation: FASEB J. 2003 Jun;17 (9):984-92
references.pmid: 12773481
references.citation: Toxicol Pathol. 1999 Jan-Feb;27(1):78-86
references.pmid: 10367678
references.citation: Cancer. 1996 Feb 1;77(3):490-8
references.pmid: 8630956
references.citation: Br J Haematol. 1993 Mar;83(3):370-83
references.pmid: 7683483
references.citation: Hum Pathol. 1992 Jul;23(7):755-61
references.pmid: 1377162
references.citation: Anticancer Res. 2001 Nov-Dec;21(6B):4325-31
references.pmid: 11908687
references.citation: Microsc Res Tech. 2003 Feb 1;60(2):186-98
references.pmid: 12539173
references.citation: Br J Cancer. 1995 Jun;71(6):1359-62
references.pmid: 7779739
references.citation: Crit Rev Oncol Hematol. 2001 Feb;37(2):97-114
references.pmid: 11166583
references.citation: J Exp Clin Cancer Res. 2003 Mar;22(1):29-33
references.pmid: 12725319
references.citation: Acta Derm Venereol. 1998 Jan;78(1):19-21
references.pmid: 9498020
references.citation: Cancer. 1994 Aug 15;74(4):1289-93
references.pmid: 8055450
references.citation: Leukemia. 1987 May;1(5):417-26
references.pmid: 2444831
references.citation: Pathol Res Pract. 2000;196(9):607-12
references.pmid: 10997734
references.citation: Prostate Cancer Prostatic Dis. 2002;5(2):123-7
references.pmid: 12497001
references.citation: Blood. 1990 Jun 15;75(12):2417-26
references.pmid: 1693532
references.citation: J Cell Biol. 1991 Sep;114(5):1059-68
references.pmid: 1874786
references.citation: J Exp Med. 1993 Aug 1;178(2):449-60
references.pmid: 8340753
references.citation: Eur J Cancer. 1996 Sep;32A(10):1686-92
references.pmid: 8983275
references.citation: J Lab Clin Med. 1993 Apr;121(4):579-87
references.pmid: 8454940
references.citation: Arch Pathol Lab Med. 2003 Jan;127(1):36-41
references.pmid: 12521364
references.citation: Endocr Rev. 1997 Feb;18(1):4-25
references.pmid: 9034784
references.citation: Vascul Pharmacol. 2002 Nov;39(4-5):225-37
references.pmid: 12747962
references.citation: Blood. 1995 Jun 1;85(11):3150-7
references.pmid: 7756647
references.citation: J Biol Chem. 1996 May 10;271(19):11090-8
references.pmid: 8626652
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: Arch Ophthalmol. 1994 Nov;112(11):1476-82
references.pmid: 7980139
references.citation: FASEB J. 2000 Jan;14 (1):55-64
references.pmid: 10627280
references.citation: Int J Cancer. 2000 Mar 20;89(2):122-6
references.pmid: 10754488
references.citation: Breast Cancer Res Treat. 1999 Jan;53(1):19-31
references.pmid: 10206069
references.citation: Eur J Cancer. 1993;29A(8):1141-5
references.pmid: 8390846
references.citation: J Clin Invest. 1997 May 15;99(10):2351-7
references.pmid: 9153276
references.citation: Proc Natl Acad Sci U S A. 1995 Nov 7;92 (23 ):10457-61
references.pmid: 7479819
references.citation: Br J Cancer. 2002 Dec 2;87(12):1422-30
references.pmid: 12454772
references.citation: Cancer Res. 1996 May 1;56(9):2013-6
references.pmid: 8616842
references.citation: Int J Cancer. 2002 Jul 10;100(2):123-30
references.pmid: 12115558
references.citation: J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):1-13
references.pmid: 11388737
references.citation: Invest Ophthalmol Vis Sci. 1996 Apr;37(5):855-68
references.pmid: 8603870
references.citation: Clin Cancer Res. 2001 Mar;7(3):524-32
references.pmid: 11297243
references.citation: J Cutan Pathol. 1997 Sep;24(8):484-93
references.pmid: 9331894
references.citation: J Biol Chem. 1997 Jul 18;272(29):18007-14
references.pmid: 9218428
references.citation: J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87
references.pmid: 1281237
references.citation: Nature. 1996 Apr 4;380(6573):435-9
references.pmid: 8602241
references.citation: Cancer. 1998 Nov 15;83(10):2139-49
references.pmid: 9827718
references.citation: Nature. 1996 Apr 4;380(6573):439-42
references.pmid: 8602242
references.citation: World J Gastroenterol. 2002 Jun;8(3):385-92
references.pmid: 12046056
references.citation: J Clin Invest. 1985 Sep;76(3):1102-6
references.pmid: 2413071
references.citation: FASEB J. 1990 Aug;4(11):2868-80
references.pmid: 2199285
references.citation: Nat Med. 1999 Jun;5(6):623-8
references.pmid: 10371499
references.citation: J Surg Oncol. 2000 Dec;75(4):252-7
references.pmid: 11135266
references.citation: N Engl J Med. 1995 Dec 28;333(26):1757-63
references.pmid: 7491141
references.citation: Hum Reprod. 1993 Feb;8(2):175-81
references.pmid: 8097204
references.citation: J Cell Sci. 1996 Feb;109 ( Pt 2):437-45
references.pmid: 8838667
references.citation: Gan To Kagaku Ryoho. 2003 May;30(5):599-605
references.pmid: 12795089
references.citation: Stroke. 1996 Oct;27(10):1865-72; discussion 1872-3
references.pmid: 8841346
references.citation: Best Pract Res Clin Haematol. 2001 Jun;14(2):241-55
references.pmid: 11686098
references.citation: Proc Natl Acad Sci U S A. 1979 Oct;76(10):5217-21
references.pmid: 291937
references.citation: Clin Cancer Res. 1995 Dec;1(12 ):1623-34
references.pmid: 9815965
references.citation: J Hematother. 1992 Summer;1(2):115-29
references.pmid: 1285404
references.citation: Surg Oncol. 1993 Dec;2(6):325-33
references.pmid: 8130939
references.citation: Anticancer Res. 1998 Sep-Oct;18(5A):3621-8
references.pmid: 9858949
references.citation: Cancer. 2004 Jul 1;101(1):51-7
references.pmid: 15221988
references.citation: J Clin Invest. 2003 Mar;111(5):707-16
references.pmid: 12618525
references.citation: J Pathol. 1990 Jul;161(3):267-71
references.pmid: 2391587
references.citation: J Biol Chem. 2002 Nov 15;277(46):43799-808
references.pmid: 12228247
references.citation: Cancer. 1998 Aug 1;83(3):498-509
references.pmid: 9690543
references.citation: Lancet. 1992 Jul 18;340(8812):145-6
references.pmid: 1378165
references.citation: Blood. 1996 Jan 1;87(1):67-72
references.pmid: 8547678
references.citation: Surg Clin North Am. 2003 Feb;83(1):61-75
references.pmid: 12691450
references.citation: Cancer Res. 1999 Feb 15;59(4):856-61
references.pmid: 10029075
references.citation: Hum Pathol. 1995 Jan;26(1):86-91
references.pmid: 7821921
references.citation: J Biol Chem. 1985 Sep 15;260(20):11300-6
references.pmid: 3161894
references.citation: Proc Natl Acad Sci U S A. 1974 May;71(5):1906-9
references.pmid: 4209883
references.citation: N Engl J Med. 1991 Jan 3;324(1):1-8
references.pmid: 1701519
references.citation: J Immunol. 1996 Feb 15;156(4):1515-24
references.pmid: 8568255
references.citation: Ann Surg Oncol. 1997 Jul-Aug;4(5):385-8
references.pmid: 9259964
references.citation: Lab Invest. 1990 Jun;62(6):690-6
references.pmid: 1694254